Summary Slide.png (76.78 kB)

Long-Term Ivacaftor in People Aged 6 Years and Older With Cystic Fibrosis With Ivacaftor-Responsive Mutations

figure

posted on 2020-09-24, 16:46 authored by Joseph M. Pilewski, Kris De Boeck, Jerry A. Nick, Simon Tian, Cynthia DeSouza, Mark Higgins, Richard B. Moss

The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

Funding

Vertex Pharmaceuticals Incorporated

History

Usage metrics

Pulmonary Therapy

Keywords

Ivacaftor Long-term efficacy Long-term safety Non-G551D mutation Residual function R117H Gating mutation

Licence

CC BY-NC 4.0